@article {1195, title = {Formulation of Creams Containing Active Fraction of Cassia fistula L. Barks and its Antibacterial Activity against Propionibacterium acnes and Pseudomonas aeruginosa}, journal = {Pharmacognosy Journal}, volume = {12}, year = {2020}, month = {June 2020}, pages = {920-928}, type = {Research Article}, chapter = {920}, abstract = {

Background: Cassia fistula L. has been traditionally used to cure skin diseases. That disease can be caused by various bacteria, such as Propionibacterium acnes and Pseudomonas aerugniosa. Objective: the objective of this research was to formulate cream containing active fraction of Cassia fistula bark and to study the antibacterial activity as well as physical stability of the active substance after formulation. Materials and Methods: The cream base were oilin- water (O/W) and water in oil (W/O) type. Antibacterial activity test had been performed by using agar diffusion method. Determination of Minimum Inhibitory Concentration (MIC) and Minimum Bactericidal Concentration (MBC) were conducted by microdilution method. The active fraction was formulated into creams with concentration of 4 -6x MIC. Physical evaluation of creams including organoleptic, pH, viscosity, TLC (Thin Layer Chromatography) profiling and antibacterial activity against both tested bacteria were evaluated during 28 days of storage. Results: The results showed that ethyl acetate fraction was the most active, having MIC and MBC values of 175 and 350 ppm respectively against P. acnes, while those against P. aeruginosa were 400 and 800 ppm. Optimation on creams using different type of cream bases showed that either O/W or W/O creams remained stable during 28 days of storage in terms of organoleptic and pH. The viscosity increased in O/W and decreased in W/O type. Qualitative analysis by TLC profiling showed that the ethyl acetate fraction of Cassia fistula as chemical compounds in creams was relatively stable as the profile remained the same after 28th day of storage. Result of antibacterial activity test on cream with O/W base was unchange after 28 day, while that with W/O revealed no activity which may due to poor diffusion within the cream base as media. Conclusion: active fraction of Cassia fistula can be formulated into cream with O/W cream base system.

}, keywords = {Antibacteria, Cassia fistula, Cream, Propionibacterium Acnes, Pseudomonas aeruginosa}, doi = {10.5530/pj.2020.12.131}, author = {Anis Yohana Chaerunisaa and Muhaimin Muhaimin and Yasmiwar Susilawati and Tiana Milanda} } @article {366, title = {Evaluation of Antidiabetic Activity of Hydroalcoholic Extract of Cassia fistula Linn. pod in Streptozotocin-Induced Diabetic Rats}, journal = {Pharmacognosy Journal}, volume = {9}, year = {2017}, month = {July 2017}, pages = {599-606}, type = {Original Article}, chapter = {599}, abstract = {

Background: Diabetes mellitus (DM) is a global health problem and the incidence of DM is increasing at alarming rate all over the world. Many Indian medicinal plants have been reported to possess potential antidiabetic activity and could play important role in the management diabetes. Objective: The present study aimed to evaluate antidiabetic activities of 70\% ethanolic extract of Cassia fistula pod in streptozotocin-induced diabetic rats. Materials and Methods: Diabetes was induced in male Wistar rats by single intraperitoneal injection of streptozotocin (60 mg/kg b.wt.). The diabetic rats were administered orally with C. fistula pod extract at three different doses (100, 250 and 500 mg/kg b.wt./day) for 60 days. The results were compared with standard drug glibenclamide (5 mg/kg b.wt./day) treated rats. Results: The streptozotocin treated diabetic control rats showed a significant increase in the blood glucose and glycosylated hemoglobin (HbA1c) levels with a concomitant decrease in the body weight and glycogen content in the liver as compared to normal control rats. Oral administration of C. fistula pod extract (100, 250 and 500 mg/kg b.wt./day) or glibenclamide for 60 days showed significant reduction in the blood glucose and HbA1c levels and an elevation in the body weight and hepatic glycogen content as compared to diabetic control rats. Furthermore, treatment with extract (500 mg/kg b.wt.) also showed improvement of oral glucose tolerance test (OGTT) in diabetic rats. These results were comparable to glibenclamide. Conclusion: The results of present study showed that C. fistula pod extract possess significant antihyperglycemic activity and supports the traditional use of C. fistula pod for the treatment of diabetes mellitus.

}, keywords = {Antidiabetic, Blood glucose, Cassia fistula, Glycogen, Glycosylated Hemoglobin, Streptozotocin}, doi = {10.5530/pj.2017.5.95}, url = {/files/pj-9-5/10.5530pj.2017.5.95/index.html}, author = {Ram Niwas Jangir and Gyan Chand Jain} }